<DOC>
	<DOC>NCT03090893</DOC>
	<brief_summary>The objective of this study will be to prospectively evaluate the response of a continuous infusion of recombinant human antithrombin concentrate (rhAT) (ATRYN®) to achieve and maintain the AT activity within a specified range in adult patients that require extracorporeal membrane oxygenation (ECMO) following cardiopulmonary bypass (CPB) and cardiac surgery.</brief_summary>
	<brief_title>Response of Continuous Recombinant Antithrombin Infusion in Postcardiotomy ECMO Patients</brief_title>
	<detailed_description />
	<mesh_term>Antithrombin III Deficiency</mesh_term>
	<mesh_term>Thrombophilia</mesh_term>
	<mesh_term>Antithrombins</mesh_term>
	<mesh_term>Antithrombin III</mesh_term>
	<criteria>Completed cardiac surgery with Cardiopulmonary Bypass and subsequently placed on venoarterial (VA) Extracorporeal Membrane Oxygenation (ECMO) support at any point during the ongoing hospitalization Serum Antithrombin &lt; 60%. Heart transplantation during ongoing hospitalization Excessive bleeding (300 ml/hr of chest tube drainage for 2 consecutive hours) Weight &lt; 40 kg Allergy to goat products Anticoagulation with a direct thrombin inhibitor Religious exception to blood products Hypothermia (&lt; 34°C)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>